Jim. morning, oncology I'll our made our XXXX on recent This progress regarding we've updates expanded you, with for XXXX ALKS focus program. primarily submission Thank and ALKS NDA important
the to also of NDA XXXX, we I that encompass disorder. treatment earlier ALKS bipolar treatment to plan schizophrenia the month, For we the submission of this expand for announced
follows bipolar to and proposed This align XXXX. the constructive on the a this the ALKS to pathway interaction for with FDA pre-NDA indications support regulatory submission
will ENLIGHTEN program clinical in olanzapine the with the the from data and NDA drug-drug from bipolar as that bridging FDA support XXXX include schizophrenia pharmacokinetic as completed data completed data XXXX filing studies and well interaction ALKS patients The ALKS to strategy. requested comparing
quarter. Our team with the preparing in the to file fourth the submit diligently is NDA plans expanded
maintenance for are adjunct These treatment or for of I treatment an disorder and with monotherapy bipolar support adults lithium and the valproate I associated monotherapy. schizophrenia episodes or adults with intended with indication disorder as or a the treatment manic a to mixed an indications data as of the for bipolar to as of
ALKS mg or to bipolar with XXXX samidorphan reflect fixed XX include for commonly mg XX of I doses olanzapine olanzapine X proposed the which spectrum Importantly, of and mg used disorder of XX dosage treat mg, schizophrenia. mg, the strength XX co-formulated
illnesses I X% the is estimated are mental serious Both more schizophrenia and of degenerative population. affect each bipolar adult than and to disorder US
antipsychotics bipolar are of Oral atypical mainstay a disorder. treatment of the
side rate However, degenerative efficacy cycle inadequate or through patients schizophrenia to risk due creates fairly a a to multiple discontinue effects. relapses. patients where at similar medications intolerable dynamic and high often may This
that bipolar disorder. adults disorder, safety weight to established concerns treatment for option to has bipolar olanzapine We suffering and in believe schizophrenia the treatment relegated despite and be to ALKS from XXXX potential has a practice, In efficacy. been second line largely gain due useful I
But take candidate. to the a XXXX program background on XXXX. Turning immuno-oncology XXXX, fronts. some design to a the step ALKS multiple and ALKS ALKS for biology, me interleukin-X the The development let novel back for hypothesis molecule is on provide progressing clinical
as I'll IL-X, natural on receptors cells refer to which interleukin-X, T tumor-killing, intermediate now doses, IL-X killer CDX high expressed positive cells. affinity to and the At binds
Recombinant and cell patients associated a subset is metastatic known patients. is responses Proleukin, complete and with melanoma approved durable and in of for with carcinoma human IL-X, as renal
the cells use limits activates preferential potently IL-X the anti-tumor despite more and syndrome, receptor activation and T IL-X regulatory significant with This profile immunosuppressive capillary higher leak established of IL-X tolerability toxicity efficacy. of its However, poor resulting expansion concern. a affinity in significantly
is intracellular of leads polypeptide initiates IL-X selectively modified and killer XXXX receptors. comprised IL-X This affinity of CDX bind IL-X intermediate binding XXXX proliferation chain. design natural ALKS and allows to stable, to cells. to cascade a of single that signaling positive a receptor The novel alpha
ALKS Importantly, of to which systemically T regulatory activation the stable design minimizes hinders affinity IL-X high of cells. bind receptors, ability its XXXX the fusion to
we data The design date and pharmacodynamic support observed have hypothesis. action our of to mechanism
of Now, I'll ARTISTRY that overview development some provide and the we then efficacy of early insight into I'll clinical brief provide signals our the status observing. a program are
parts distinct daily XXXX escalation, ARTISTRY-X settings. three combination consecutive intravenously trial and with evaluating – in combination The monotherapy dose days stage for administered checkpoint monotherapy comprised is a study expansion The inhibitor, is and monotherapy five both the ongoing of pembrolizumab.
The refractory monotherapy all-comer designed escalation in with pharmacodynamic tumors. was assess stage advanced solid ARTISTRY-X to of dose the markers patients
escalation Data day from T effects per and spanning and X circulating of five dose a kg X.X immunosuppressive cells dose the effect cohorts, killer range and µg completed non-dose regulatory a have dose-dependent natural pharmacodynamic µg demonstrated per T on minimal cells. kg per to CDX-positive dependent of cells
cell These T in to with effective data IL-X. are consistent would see expect you with with high-dose our line what pretest with hypothesis, expansion
completed see chills side therapy with cohorts as one effect consistent expect hypertension. was the what to fever, low-grade such across The would with profile and cytokine
capillary has date. to syndrome leak no been observed Importantly,
the portion data, with therapies. announced carcinoma refractory to of in June, ALKS expansion renal safety II melanoma, these and monotherapy cell efficacy, of the tolerability in as the evaluate patients we on Based ARTISTRY-X of or PD-X to initiation XXXX prior Phase
expansion Treg of The µg out identification the per for XXXX per achieve monotherapy the escalation. followed activation dose recommended dose to in day. advance tolerability X our II decisions corresponding along of lymphocyte demonstrated we desired cell set Phase the Data with dose from kg profile this to expansion without
In this of and efficacy melanoma cohort carcinoma, XXX objective monotherapy will renal we ALKS to expansion measures patients. in XXXX assess cell up in
these treatment inpatient cohorts PD-X options. currently patients very both on outpatient enrolling often limited in settings. These and disease are Following therapy, have progression
our clinically, efficacy monotherapy these have there observed potential XXXX have remains to is impact we that for ALKS expansions tumor types. hypothesis cell the Given the initial in
patients of In monotherapy ALKS ongoing and with types in stage pembrolizumab enrolling steadily ARTISTRY-X, of parallel in inpatient dose evaluating outpatient a we cohorts, to in and the variety escalation combination expansion will tumor in XXXX combination the both settings. also be
express well cell low Cohorts metastatic PD-X approved that or non-small subjects both and including tumors patients whose tumor treatment as in carcinoma, time breast, as at sarcomas types unapproved were colorectal, of levels. lung cancer we to evaluating enrollment triple-negative the with are soft refractory types undetectable tumor tissue naïve ovarian and PD PD-LX
with recently portion three on lung feedback, evaluating squamous ARTISTRY-X cohorts cell patients cell the add and and head cancer line therapy neck to line Based non-small melanoma, expanded second second investigator carcinoma. we first-line combination of
XX the of reviewed in and in the fourth cohort. this patients cohort we've last are year, initiation enrollment indicated these new quarter patients PD-X therapy Since unapproved toxicities. Data nearing no have completion of enrolled in combination tumors approximately date to of from
being Given subjects. to the may observed, enrollment we enroll trends initial and additional signals this cohort expand
to earlier addition ARTISTRY-X, year, to every safety, administered ARTISTRY-X, weeks. once I/II In our initiated this tolerability and ALKS subcutaneously and the three we study of explore once efficacy Phase weekly XXXX
µg dose per which off we have day the to once is solid is ARTISTRY-X of to to initial per regimen. correspond at of X.X fully IV as the intended roughly cohort times weekly five kg XXXX, start ALKS X enrolled of the mg
cohort currently demonstrated previously CDX on NK XXXX minimal therapy similar day this All seven µg these we expansion, pharmacoeconomic patients X activation patients remain positive have corresponding and the to Tregs. and have dose with per of observed from from at initial per of IV initial kg what cell data
that efficacy ultimate of into of or and clear I'll provide we yet have seeing but to the momentum, sample is months note XXXX. picking the potential size is data up final are enrollment activity small not a therapy the while ALKS I'll insights relatively some do have view into sufficient we today,
the seen context of have this signals ARTISTRY in With program. efficacy we mind, initial across
disease in stabilization the at dose ARTISTRY-X, also treatment µg monotherapy kg X per starting of per as we day dose used observed stage escalation When level. the
the see kg X and in this of monotherapy patients at appears kg XX their of doses, much on as patient we terms completed µg these to all-cover scans the expect per treatment. majority refractory who to µg date X cutoff in stable efficacy While June disease didn't first of activity Clinical upon day be population, continued on-study to per the XX per second benefit disease scan. of as X stable eight demonstrated maintained have of
we also signs have In observed of the ARTISTRY-X, portion of activity. initial combination antitumor
types. June, patients on-study five Also, completed had on better disease initial the nine their XX All first demonstrated as scans. of of stable who PD-X or five scans, patients tumor unapproved
will We data to and this these to year. continue mature details disclose additional to later plan allow
of into initial XXXX ARTISTRY-X subcutaneous In study, weeks moving patients prior monotherapy an receive six combination. to
period on combination have lead-in initial the of we week during the period study. these to look six forward advance short, as the While and monotherapy is initial stage scan observed disease following monotherapy they XXXX stabilization patients the into the
feedback been from program. Across medical across community trends the engagement far encouraging the thus at ASCO enrollment and accelerating program, with the positive, has leader the thought
more a into are look congress we detailed the and XXXX forward a profile ALKS fall about this expect We meeting to at providing data learn moving period medical more acceptance. to of [ph] pending
forms on collaboration for diroximel multiple relapsing of call Before developed back Biogen brief I novel being update fumarate oral a in the I'll turn fumarate, to with Rich, provide a sclerosis.
action quarter for in our XXXX the fumarate in year. of December the regulatory NDA NDA fourth and We submission expect on of submitted this diroximel
to expect head-to-head the evaluating EVOLVE-MS-X study which of against continue the profile diroximel is the gastrointestinal soon. We of tolerability fumarate TECFIDERA results
part Data profile EVOLVE-MS-X DRF. from regulatory labeling intended of the purposes. tolerability are upon of the differentiated to The the or build demonstrating designed our existing GI evidence of package the study body for was not
forward the they agency working NDA to look as we meantime, the their review complete of In with the submission.
call Now, I'll over turn Richard. the to
